Stockscreener 앱 받기
445.12
3.56%
15.32
시간 외 거래:
445.12
전일 마감가:
$429.80
열려 있는:
$432.87
하루 거래량:
908.14K
Relative Volume:
0.83
시가총액:
$58.81B
수익:
$3.21B
순이익/손실:
$43.57M
주가수익비율:
1,850.81
EPS:
0.2405
순현금흐름:
$221.36M
1주 성능:
-3.39%
1개월 성능:
-3.95%
6개월 성능:
+53.51%
1년 성능:
+75.69%
1일 변동 폭
$430.27
$447.69
1주일 범위
$420.30
$467.73
52주 변동 폭
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
명칭
Alnylam Pharmaceuticals Inc
전화
(617) 551-8200
주소
675 WEST KENDALL STREET, CAMBRIDGE, MA
ALNY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-04 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-08-04 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2025-03-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-12 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-02-16 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2023-10-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-05-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 개시 | SMBC Nikko | Neutral |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Buy |
| 2022-09-09 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-06-07 | 개시 | William Blair | Outperform |
| 2022-04-25 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-01-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-11-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 재개 | Berenberg | Hold |
| 2020-09-08 | 개시 | Citigroup | Buy |
| 2020-08-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 재개 | Evercore ISI | Outperform |
| 2020-03-19 | 개시 | Berenberg | Buy |
| 2019-12-19 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-20 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-03-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 재확인 | Stifel | Buy |
| 2018-08-07 | 업그레이드 | Stifel | Hold → Buy |
| 2018-05-04 | 재확인 | Stifel | Hold |
| 2018-03-28 | 개시 | Evercore ISI | In-line |
모두보기
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Thanksgiving: Top 10 Most Innovative BioPharma Drugs In Phase 3 - Seeking Alpha
A Look at Alnylam Pharmaceuticals's Valuation Following Raised Sales Guidance on Vutrisiran Outperformance - simplywall.st
Here’s What Boosted Alnylam Pharmaceuticals (ALNY) in Q3 - MSN
Backdoor AI Beneficiary Yields 8.8%, Trades at 13% Discount - Investing.com
MoA Mid Cap Growth Fund's Alnylam Pharmaceuticals Inc(ALNY) Holding History - GuruFocus
Alnylam Pharmaceuticals (ALNY): Assessing Valuation After Recent Share Price Pullback - Yahoo Finance
Is Alnylam Pharmaceuticals Stock Justified After 73.9% Surge and Clinical Trial Milestones? - simplywall.st
Small Interfering RNA (siRNA) Therapeutics Market 2025: - openPR.com
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years - Benzinga
Alnylam's ATTR cardiomyopathy drug backed for NHS use - pharmaphorum
NICE Final Draft Guidance backs Alnylam’s Amvuttra - The Pharma Letter
Why Alnylam Pharmaceuticals Inc. (DUL) stock attracts wealthy investorsJuly 2025 Institutional & Expert Approved Trade Ideas - newser.com
Alnylam Pharmaceuticals Faces Weak Start with 6.56% Gap Down Amid Market Concerns - Markets Mojo
UK's drug-cost watchdog recommends Alnylam's heart disease drug - Reuters
High-Flying Biotech Stock Sets Up After 96% Pop; Profitability In Sight As Key Drug Sales Double - MSN
Is Alnylam Pharmaceuticals Inc. stock cheap at current valuationJuly 2025 Decliners & High Return Stock Watch Alerts - newser.com
Will Alnylam Pharmaceuticals Inc. (DUL) stock sustain bullish trend into 2025 - newser.com
Will Alnylam Pharmaceuticals Inc. stock deliver consistent dividendsTrade Analysis Report & Daily Growth Stock Investment Tips - newser.com
Is Alnylam Pharmaceuticals Inc. stock a defensive play in 2025Weekly Profit Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
How Alnylam Pharmaceuticals Inc. (DUL) stock reacts to fiscal policiesWeekly Trading Summary & Real-Time Volume Analysis - newser.com
Regression analysis insights on Alnylam Pharmaceuticals Inc. performance2025 Top Gainers & Reliable Volume Spike Alerts - newser.com
Will Alnylam Pharmaceuticals Inc. continue its uptrendEarnings Miss & Smart Money Movement Tracker - newser.com
VP Fitzgerald Sells 12,128 ($5.5M) Of Alnylam Pharmaceuticals Inc [ALNY] - TradingView
[Form 4] ALNYLAM PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
How risky is Alnylam Pharmaceuticals Inc. (DUL) stock compared to peers2025 Top Decliners & Expert Approved Trade Ideas - newser.com
How dovish Fed policy supports Alnylam Pharmaceuticals Inc. (DUL) stockQuarterly Profit Report & Reliable Intraday Trade Alerts - newser.com
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-19-2025 11 - MarketScreener
Is Alnylam Pharmaceuticals Inc. (DUL) stock a fit for income portfolios2025 Price Targets & Smart Swing Trading Techniques - newser.com
What data driven models say about Alnylam Pharmaceuticals Inc.’s futureVolume Spike & Fast Moving Stock Watchlists - newser.com
How to recover losses in Alnylam Pharmaceuticals Inc. stockPortfolio Update Report & Verified Momentum Stock Alerts - newser.com
Alnylam Pharmaceuticals Inc (ALNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.03%
1.63%
자본화:
|
볼륨(24시간):